home / stock / biib / biib articles

BIIB Articles, Biogen Inc. - From 05/25/24

Stock Information
Company Name: Biogen Inc.
Stock Symbol: BIIB
Market: NASDAQ
Website: biogen.com
Menu
BIIB BIIB Quote BIIB Short BIIB News BIIB Articles BIIB Message Board
Get BIIB Alerts

News, Short Squeeze, Breakout and More Instantly...
Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Biogen Inc. (BIIB) | Benzinga

SAN DIEGO, May 24, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of persons and enti...
BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc. | Benzinga

NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Biogen Inc. (NASDAQ:BIIB)? Did you purchas...

BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | Benzinga

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notif...

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm | Benzinga

LOS ANGELES, May 23, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class a...
BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead the Biogen Class Action Lawsuit | Benzinga

SAN DIEGO, May 22, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Biogen class action lawsuit seeks to represe...

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences | Benzinga

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of im...

Larimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed Drug | Benzinga

On Monday, Larimar Therapeutics Inc (NASDAQ:LRMR) announced that the FDA removed the previous partial clinical hold on&nbs...
Ionis, Biogen Down on Ending Development of ALS Drug | Benzinga

Shares of Ionis Pharmaceuticals (NASDAQ: IONS) and Biogen (NASDAQ: BIIB) lost at least 2% in market cap on Thursday after the companies announced t...

Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another | Benzinga

Thursday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Biogen Inc (NASDAQ:BIIB) decided to terminate the development of BII...

Jim Cramer Likes Micron And Its CEO, Recommends Buying This Big Bank | Benzinga

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Micron (NASDAQ:MU), adding that he likes the company and its ...
Previous 10 Next 10